Defense World
01 Feb 2026, 09:38 UTC · 33w ago
Verdict
Headline leans bearish. We score SRPT +0.80 across one claim.
Score contradicts the headline.
Leans bearish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish
Sarepta Therapeutics reported three-year top-line results from the EMBARK Phase 3 trial showing a disease-modifying impact for ELEVIDYS in DMD patients.
More positive than 99% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 87% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 87% of ticker scores this week
The company reported positive three-year top-line results from a pivotal trial demonstrating a disease-modifying impact for its gene therapy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
5h ago
−9.6%
Price is moving against the score
$18.39 vs $20.34 close before publication (Jan 30) · not market-adjusted
SRPT chart →
